"Gliquidone is an anti-diabetic drug in the sulfonylurea class. It is used in the treatment of diabetes mellitus type 2. It is an ATP-dependent K+ (KATP) channel blocker. This block causes a depolarization which leads to activation of voltage-dependent Ca channels and Ca2+ influx, and eventually increases insulin release."@en . . . . "Glurenorm"@en . . . . . . . . . . . . . . . . "approved"@en . . . "The mean terminal half-life was approximately 8 hours (range 5.7-9.4 hours)"@en . . . . . . . . "33342-05-1"@en . . . . "Humans and other mammals"@en . "Gliquidone"@en . " "@en . . . . "Used in the treatment of diabetes mellitus type 2."@en . . "The mechanism of action of gliquidone in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells, and increasing sensitivity of peripheral tissues to insulin. Gliquidone likely binds to ATP-sensitive potassium channel receptors on the pancreatic cell surface, reducing potassium conductance and causing depolarization of the membrane. Membrane depolarization stimulates calcium ion influx through voltage-sensitive calcium channels. This increase in intracellular calcium ion concentration induces the secretion of insulin."@en . . . "U.S. Patent 3,708,486."@en . . . .